Research programme: equine encephalitis virus vaccine - Maxygen

Drug Profile

Research programme: equine encephalitis virus vaccine - Maxygen

Alternative Names: Eastern equine encephalitis virus vaccine - Maxygen; Maxy 829; Maxy-EE; Vaccines against encephalitis alphaviruses - Maxygen; Venezuelan equine encephalitis virus vaccine - Maxygen; Western equine encephalitis virus vaccine - Maxygen

Latest Information Update: 02 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Maxygen
  • Developer Maxygen; United States Army Medical Research Institute of Infectious Diseases
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Eastern equine encephalomyelitis; Venezuelan equine encephalomyelitis; Western equine encephalitis virus infections

Most Recent Events

  • 10 Jun 2013 Discontinued - Preclinical for Encephalitis virus infections in USA (Parenteral)
  • 18 Sep 2008 Preclinical development is ongoing
  • 18 Sep 2008 This equine encephalitis vaccine programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top